Inventor · disambiguated record
Christopher F. Nicodemus
Also filed as: NICODEMUS CHRISTOPHER F
9 granted patents·9 pending applications·25 citations·filing 1989–2023
82Inventor score
Files withONCOQUEST INC6ADVANCED IMMUNE THERAPEUTICS INC2BRIGHAM & WOMENS HOSPITAL2SCHULTES BIRGIT C2ALTAREX MEDICAL CORP1
Top patents by PatentIndex Score
18 records- 0180US10537636B2Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvantONCOQUEST INC·Filed 2017·Granted Jan 21, 2020·1 cites·6 claims
- 0275US8697079B2IgE antibodies for the treatment of cancerPENICHET MANUEL L·Filed 2012·Granted Apr 15, 2014·5 cites·18 claims
- 0374US11351255B2Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvantONCOQUEST INC·Filed 2019·Granted Jun 7, 2022·0 cites·11 claims
- 0471US8038994B2Combination therapy for treating diseaseQUEST PHARMATECH INC·Filed 2004·Granted Oct 18, 2011·3 cites·20 claims
- 0571US2008311127A1Combination therapy for treating diseaseALTAREX MEDICAL CORP·Filed 2007·Application pending·0 cites
- 0663US2020206347A9Method of indirect immunization of human ovarian cancer patients through selection of xenogeneic immunoglobulin fc portionsONCOQUEST INC·Filed 2017·Application pending·0 cites
- 0762US2025066504A1Use of oregovomab and parp inhibitors for treatment of ovarian cancerCANARIABIO INC·Filed 2023·Application pending·0 cites
- 0859US5171674APolynucleotides that encode the human proteoglycan peptide core of the effector cells of the immune responseBRIGHAM & WOMENS HOSPITAL·Filed 1989·Granted Dec 15, 1992·16 cites·9 claims
- 0954US2018221476A1Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvantONCOQUEST NC·Filed 2017·Application pending·0 cites
- 1050US2011256124A1METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASEADVANCED IMMUNE THERAPEUTICS INC·Filed 2010·Application pending·0 cites
- 1150US2019322760A1Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy of cancerONCOQUEST INC·Filed 2019·Application pending·0 cites
- 1246US10392444B2Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancerONCOQUEST INC·Filed 2015·Granted Aug 27, 2019·0 cites·9 claims
- 1346US2005031619A1Therapeutic compositions that alter the immune responseFiled 2002·Application pending·0 cites
- 1444US8945566B2Methods for improving the bioactivity of therapeutic IgE antibodies for the treatment of diseaseSCHULTES BIRGIT C·Filed 2012·Granted Feb 3, 2015·0 cites·8 claims
- 1544US2005271649A1Therapeutic adjuvantSCHULTES BIRGIT C·Filed 2003·Application pending·0 cites
- 1641US10975163B2Methods of increasing delivery of anti-cancer agents to targetsONCOQUEST INC·Filed 2016·Granted Apr 13, 2021·0 cites·8 claims
- 1736US2011091466A1IgE ANTIBODIES FOR THE TREATMENT OF CANCERADVANCED IMMUNE THERAPEUTICS INC·Filed 2010·Application pending·0 cites
- 1827US5317085APolynucleotides that encode the human proteoglycan peptide core of the effector cells of the immune responseBRIGHAM & WOMENS HOSPITAL·Filed 1992·Granted May 31, 1994·0 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when Christopher F. Nicodemus files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →